Nippon Fine Chemical Co., Ltd.
4362・Prime Market・Chemicals
Business
Nippon Fine Chemical Co., Ltd. is a specialty chemicals manufacturer founded in 1918, forming a group that includes 5 consolidated subsidiaries. In its core Functional Products segment, the company globally deploys phospholipids and functional oils for cosmetics use (Beauty Care), high-purity phospholipids and liposome formulations for pharmaceutical use (Healthcare), and materials for perovskite solar cells and wool grease derivatives (Fine Chemical). In the Environmental Hygiene Products segment, its subsidiary Arbrose Co., Ltd. manufactures and sells commercial-use hygiene products for the medical, nursing care, and food factory sectors. The company's main customers are domestic and overseas pharmaceutical and cosmetics brands, and it is listed on the Prime Market of the Tokyo Stock Exchange.
Business Model
The Functional Products segment accounts for approximately 78% of net sales and boasts a high profitability with an operating margin of 17.8% (FY2026, ending March 2026). In addition to manufacturing at the company's own plants (Takasago and Kakogawa-Higashi), the company has built a production and sales structure that leverages its overseas bases in China and Taiwan. Differentiating itself through high-purity, high-functionality products such as phospholipids for pharmaceutical use, it secures stable earnings through direct sales to global pharmaceutical companies such as Gilead Sciences. The company maintains an R&D expense ratio of 2.8% of net sales, continuing to differentiate its products through technological innovation.
Company Strengths
The company successively built a phospholipid manufacturing plant for pharmaceutical use (2017) and a dedicated liposome plant (2023) at its Takasago Plant, establishing a stable supply system for overseas pharmaceutical companies including Gilead Sciences. In FY2026 (ending March 2026), sales in the Healthcare segment reached ¥7,443 million (up 23.0% year on year) and operating profit reached ¥1,442 million (up 41.0% year on year), achieving high growth.
The company has independently developed products compliant with RSPO certification, Non-GMO, COSMOS certification, and ISO16128, building a product lineup that meets demand from Western cosmetics brands. It also promotes open innovation with customers and universities through its own open lab, "The Design & Creation Lab.", and continues to expand sales into the global market.
As of the end of FY2026 (ending March 2026), interest-bearing debt stood at ¥22 million, maintaining a virtually debt-free management structure, with cash and cash equivalents of ¥13,341 million. Net assets reached ¥52,390 million (total assets of ¥65,421 million), maintaining a high equity ratio. This financial foundation is driving the company's ability to fund its four-year, ¥135 million capital investment plan entirely from internal resources.
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) declined to ¥33,796 million (down 5.2% year on year), reflecting the impact of withdrawal from a trading subsidiary under the medium-term management plan. However, on the profit side, operating profit reached ¥5,341 million (up 9.1%), ordinary profit reached ¥5,570 million (up 6.9%), and profit attributable to owners of parent reached ¥4,428 million (up 14.4%), each renewing the highest level of the past five fiscal years. The recording of a gain on sale of investment securities of ¥916 million also boosted net profit. Comprehensive income increased substantially to ¥7,231 million (versus ¥3,181 million in the previous period), driven by an increase in valuation difference on available-for-sale securities (¥2,224 million). For FY2027 (ending March 2027), the company forecasts revenue of ¥37,400 million (up 10.7% year on year) and operating profit of ¥5,700 million (up 6.7%), anticipating that the impact of the withdrawal from the Trading segment will run its course and that Functional Products will continue to grow.
Growth Strategy
Global value-addition in pharmaceuticals and cosmetics, and social implementation of perovskite solar cell materials
Through increased overseas sales of pharmaceutical-grade phospholipids and the capture of spot demand for contract-manufactured pharmaceutical intermediates, net sales in the Healthcare field for FY2026 (ending March 2026) reached ¥7,443 million (up 23.0% year on year), and operating income reached ¥1,442 million (up 41.0% year on year). Efforts to strengthen cost competitiveness through production consolidation at the new plant are also underway.
Through increased overseas sales of industrial wool grease derivatives and cost reductions, operating income in the Fine Chemical Products field for FY2026 (ending March 2026) reached ¥1,078 million (up 109.9% year on year), more than doubling. This contributed significantly to the improvement in the overall profit margin of the Functional Products segment.
In line with the Medium-Term Management Plan, one trading subsidiary was divested from the Group, resulting in net sales in the Trading field of ¥4,476 million (down 42.9% year on year). The elimination of the low-profitability business improved the profit margin of the Functional Products segment to 17.8% (from 15.2% in the previous fiscal year), realizing a qualitative transformation of the earnings structure.
Aiming to enter the next-generation energy field, the company continues to invest in R&D toward establishing mass-production technology for materials used in perovskite solar cells. Under a policy of building a sustainable growth foundation based on three pillars—human capital investment, capital expenditure, and R&D investment—capital expenditures on tangible fixed assets for FY2026 (ending March 2026) expanded to ¥2,815 million compared with the previous fiscal year.
The company aims to capture growing demand from European and US brands for environmentally conscious cosmetics ingredients, including RSPO-, Non-GMO-, and ISO16128-compliant products. In the Beauty Care Products field for FY2026 (ending March 2026), although sales of cosmetics-grade wool grease derivatives increased, net sales declined to ¥8,548 million (down 4.3% year on year) due to delays in inventory adjustments for functional oils in overseas distribution channels, among other factors. Trends in inventory adjustment continue to warrant close attention.
Last updated: July 19, 2026